tradingkey.logo
搜尋

Ginkgo Bioworks Holdings Inc

DNA
添加自選
8.590USD
0.0000.00%
收盤 05/13, 16:00美東報價延遲15分鐘
535.37M總市值
虧損本益比TTM

Ginkgo Bioworks Holdings Inc

8.590
0.0000.00%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

-14.78%

1月

+28.59%

6月

+7.38%

今年開始到現在

+3.37%

1年

+5.79%

TradingKey Ginkgo Bioworks Holdings Inc股票評分

單位: USD 更新時間: 2026-05-13

操作建議

Ginkgo Bioworks Holdings Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名170/383位。機構持股佔比非常高,近一月多位分析師給出公司評級為賣出。最高目標價為10.00。中期看,股價處於平穩狀態。近一個月,市場表現較強,基本面評分較高,但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Ginkgo Bioworks Holdings Inc評分

相關信息

行業排名
170 / 383
全市場排名
305 / 4487
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Ginkgo Bioworks Holdings Inc亮點

亮點風險
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
估值合理
公司最新PE估值-1.61,處於3年歷史合理位
機構減倉
最新機構持股33.44M股,環比減少12.65%
莫瑞·斯塔爾持倉
明星投資者莫瑞·斯塔爾持倉,最新持倉5.89K股

分析師目標

基於 3 分析師
賣出
評級
10.000
目標均價
+15.34%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Ginkgo Bioworks Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Ginkgo Bioworks Holdings Inc簡介

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
公司代碼DNA
公司Ginkgo Bioworks Holdings Inc
CEOKelly (Jason)
網址https://investors.ginkgobioworks.com/
KeyAI